Table 4.
Icatibant injections per attack
| Parameter | Patients with HAE‐C1‐INH | |
|---|---|---|
| Germany (N = 93) | Other countriesh (N = 592) | |
| Icatibant‐treated attacksa | ||
| Patients treated with icatibant, n | 63 | 449 |
| Attacks treated with icatibant per patient | ||
| Mean (SD) | 8.7 (12.4) | 8.8 (18.4) |
| Median (IQR) | 4.0 (1.0–10.0) | 3.0 (1.0–8.0) |
| Number of injections of icatibant per attack | ||
| Attacks (%) treated with icatibant, n | 544 | 3770 |
| 1 | 528 (97.1) | 3454 (91.6) |
| 2 | 12 (2.2) | 288 (7.6) |
| 3 | 4 (0.7) | 24 (0.6) |
| 4 | 0 (0.0) | 3 (0.1) |
| 6 | 0 (0.0) | 1 (0.0) |
| P < 0.0003g | ||
| Untreated attacks in year prior to IOS entryb | ||
| Patients with at least one untreated attack, n | 46c | 229d |
| Untreated attacks per patient | ||
| Mean (SD) | 6.2 (10.7) | 7.8 (15.0) |
| Median (IQR) | 1.0 (0.0–7.0) | 2.0 (0–8.0) |
| Untreated attacks in the IOS observation perioda | ||
| Patients with at least one untreated attack, n | 31e | 206f |
| Untreated attacks per patient | ||
| Mean (SD) | 15.0 (26.6) | 7.9 (17.1) |
| Median (IQR) | 1.0 (0.0–19.0) | 1.0 (0–8.0) |
a
Attacks in year prior to IOS entry and through the IOS observation period.
b
Untreated attacks were defined as attacks not treated with icatibant or any other treatment.
c
36 patients had no untreated attacks.
d
111 patients had no untreated attacks.
e
28 patients had no untreated attacks.
f
146 patients had no untreated attacks.
g
Comparison of one injection vs. more than one injection.
h
Other countries include Austria, Brazil, Czech Republic, Denmark, France, Greece, Israel, Italy, Spain, Sweden and United Kingdom.
HAE, hereditary angioedema; IOS, Icatibant Outcome Survey; IQR, interquartile range; SD, standard deviation.